William Blair Downgrades Cardiff Oncology to Market Perform
William Blair analyst Andy Hsieh downgrades Cardiff Oncology (NASDAQ:CRDF) from Outperform to Market Perform.
Read original at benzingaStocks · News reference
Cardiff Oncology shares are trading lower after the company announced a $10 million offering of 8,571,429 shares of its common stock and accompanying warrants at $1.05 per share and accompanying warrant.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 15, 2026, 12:04 PM
- Checked
- Jul 15, 2026, 12:04 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 44.4% to $1.56 during Tuesday's after-market session. The company's market cap stands at $4.5 million. As per the news, the Q2 earnings report
Read original at benzingaCardiff Oncology Q2 EPS $(0.14) Beats $(0.16) Estimate, Sales $104.000K Beat $70.714K Estimate
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 33.33 percent increase over losses of $(0.21) per share from
Read original at benzinga8-K filing — Cardiff Oncology, Inc. (CRDF)
Filed: 2026-07-16 AccNo: 0001193125-26-305467 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgar